Cellino Launches U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Hospital-Based Foundry at Mass General Brigham Paves the Way for Decentralized, Personalized Cell and Tissue Replacements

Cellino Launches U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Cellino today announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry. Powered by Cellino’s AI-driven Nebula technology, this initiative sets the stage for a nationwide network of decentralized biomanufacturing hubs designed to deliver personalized cell and tissue therapies directly at the point of care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224202433/en/

Cellino Co-Founder & CEO Nabiha Saklayen, Ph.D., holding a Cellino Nebula cassette (Photo: Cellino)

“Massachusetts remains the best state for unique partnerships to accelerate breakthroughs, create jobs, and change patients’ lives on a global scale,” said Massachusetts Economic Development Secretary Yvonne Hao, who serves as the Board Co-Chair of the Massachusetts Life Sciences Center. “We are so incredibly proud to have two leaders in industry and healthcare collaborate on next generation biomanufacturing. Today’s announcement exemplifies the projects we must continue to champion in the next chapter of the Commonwealth’s Life Sciences Initiative.”

At the heart of this initiative is the innovative Foundry—a fully integrated, on-site facility that manufactures high-quality, patient-specific stem cells. Located at Massachusetts General Hospital, the Foundry will leverage the Nebula platform to produce clinical-grade iPSCs and derivative therapies with unmatched precision and scalability for clinical-grade manufacturing. Nebula is a closed cassette advanced biomanufacturing system that is autonomous and deployable at the point of care, ensuring robust, reproducible, and contamination-free production.

“Centralized production of cell and gene therapies is not only expensive but also limits scalability,” explained Nathan Yozwiak, Head of Research, Mass General Brigham GCTI. “Decentralizing manufacturing through autonomous, on-site facilities may significantly cut costs and shorten the timeline from early clinical research to widespread commercial application.”

The Foundry’s first clinical application focuses on a novel Parkinson’s therapy using patient-specific iPSCs. Neurosurgeon Jeffrey Schweitzer, M.D., Ph.D., the George A. Lopez, MD Endowed Chair in Neurosurgery, is leading a Phase 1 trial at Mass General Brigham. “Using a patient’s own cells as a starting point has clear advantages such as minimizing rejection risks, but making personalized cell therapy available to the millions who need it is a daunting task,” Dr. Schweitzer noted. “This collaboration represents a step toward reaching that goal.”

“Our work with GCTI represents a major leap in making regenerative medicine more accessible and efficient,” said Nabiha Saklayen, Ph.D., CEO & Co-Founder of Cellino. “By integrating advanced AI-driven bioprocessing into hospital settings, we’re transforming traditional, centralized manufacturing into a faster, cost-effective, and patient-centric model.”

About Cellino

Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients worldwide. Learn more at www.cellinobio.com and follow us on LinkedIn and X.